WendyWoods-SwaffordMDMPH

Pediatric Hematology & Oncology • Des Moines, IA

Vice President and Medical Director Blank Children’s & Women’s Services

Join to view full profile

Dr. Woods-Swafford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Woods-Swafford's full profile

Already have an account?

Office
1200 Pleasant St
Des Moines, IA 50309
Phone+1 515-241-6212

Fax+1 515-241-5994
Is this information wrong?

Summary

Vice President and Medical Director Blank Children's and Women's Services

Blank-Stoddard AYAO program, partnership between private adult and employed pediatric oncology programs in a community based cancer center

Medical Director of the Blank Children's Cancer and Blood Disorder Center (10-21)

Blank Principal Investigator for COG (10-19)

Education & Training

Vanderbilt School of MedicineMPH, 2006 - 2008
Vanderbilt University Medical CenterFellowship, Pediatric Hematology/Oncology, 2005 - 2008
Central Iowa Health System (Iowa Methodist Medical Center)Residency, Pediatrics, 2002 - 2005
University of Missouri Kansas City School of MedicineClass of 2002

Certifications & Licensure

IA State Medical License 2002 - 2024
TN State Medical License 2007 - 2008
American Board of Pediatrics Pediatrics
American Board of Pediatrics Hospice and Palliative Medicine
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Excellence in Patient Experience Award Q1 Clinics UnityPoint Des Moines, 2019
Excellence in Patient Experience Award - Overall Clinic UnityPoint Health Des Moines, 2018
Excellence in Patient Experience Award Q1 Clinics UnityPoint Health Des Moines, 2018
Patient Centered Specialty Practice NCQA, 2017
Merit Award American Society of Clinical Oncology, 2008
Join now to see all

Clinical Trials

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors Start of enrollment: 1996 Dec 01
Completed
Surgery in Treating Children With Neuroblastoma Start of enrollment: 1998 Mar 01
Completed
Phase 3
Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma Start of enrollment: 1998 Dec 01
Completed
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Start of enrollment: 2000 Jun 01
Completed
Phase 3
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Start of enrollment: 2001 May 01
Completed
Phase 3
Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia Start of enrollment: 2002 Aug 01
Completed
Phase 2
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Start of enrollment: 2003 Dec 29
Completed
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes Start of enrollment: 2004 Nov 01
Completed
Not Applicable
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma Start of enrollment: 2006 Apr 01
Completed
Phase 2
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 3
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin Start of enrollment: 2007 May 01
Completed
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Start of enrollment: 2007 Oct 08
Completed
Phase 3
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Start of enrollment: 2008 Jun 23
Completed
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Start of enrollment: 2009 Dec 07
Completed
Phase 3
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]) Start of enrollment: 2009 Feb 03
Completed
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2010 Aug 09
Completed
Phase 1, Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Start of enrollment: 2010 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Start of enrollment: 2011 Jan 26
Completed
Phase 2, Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy Start of enrollment: 2014 Jul 30
Active, not recruiting
Not Applicable
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 2012 Feb 21
Active, not recruiting
Phase 3
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Start of enrollment: 2012 Jul 05
Completed
Phase 2
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder Start of enrollment: 2013 Jan 10
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Start of enrollment: 2013 Jun 17
Active, not recruiting
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Start of enrollment: 2013 Apr 08
Active, not recruiting
Phase 1
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Start of enrollment: 2013 Sep 25
Completed
Phase 3
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Active, not recruiting
Phase 2
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma Start of enrollment: 2013 Dec 24
Completed
Phase 2
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Start of enrollment: 2014 Oct 04
Active, not recruiting
Phase 3
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma Start of enrollment: 2015 Mar 19
Active, not recruiting
Phase 3
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Start of enrollment: 2014 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
Active, not recruiting
Phase 2, Phase 3
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Start of enrollment: 2014 Sep 29
Completed
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Start of enrollment: 2014 Dec 12
Active, not recruiting
Phase 3
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase Start of enrollment: 2015 Oct 22
Completed
Phase 3
Project: Every Child for Younger Patients With Cancer Start of enrollment: 2015 Nov 03
Recruiting
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma Start of enrollment: 2016 Feb 04
Completed
Phase 2
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Start of enrollment: 2015 Dec 23
Active, not recruiting
Phase 3
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Start of enrollment: 2016 Jun 01
Active, not recruiting
Phase 3
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors Start of enrollment: 2016 Apr 04
Active, not recruiting
Phase 2
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Start of enrollment: 2016 Sep 30
Active, not recruiting
Phase 2
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Start of enrollment: 2017 Nov 17
Active, not recruiting
Phase 2
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Start of enrollment: 2017 Apr 01
Active, not recruiting
Phase 2
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology Start of enrollment: 2016 Nov 21
Completed
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Start of enrollment: 2017 May 18
Active, not recruiting
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Start of enrollment: 2012 Feb 29
Active, not recruiting
Phase 3
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Start of enrollment: 2017 Jun 19
Recruiting
Phase 2
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Start of enrollment: 2017 Aug 08
Recruiting
Phase 3
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma Start of enrollment: 2017 Jun 05
Active, not recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Start of enrollment: 2017 May 25
Recruiting
Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Start of enrollment: 2018 May 14
Active, not recruiting
Phase 3
Work Ability in Young Adult Cancer Survivors Start of enrollment: 2018 Mar 13
Completed
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Start of enrollment: 2017 Jun 01
Suspended
Phase 3
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Start of enrollment: 2017 Jul 31
Recruiting
Phase 2
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2017 Dec 18
Active, not recruiting
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors Start of enrollment: 2017 Dec 06
Active, not recruiting
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Jun 05
Active, not recruiting
Phase 2
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Apr 17
Recruiting
Phase 2
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Nov 13
Active, not recruiting
Phase 2
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Nov 28
Active, not recruiting
Phase 2
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Oct 30
Active, not recruiting
Phase 2
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Aug 23
Active, not recruiting
Phase 2
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Nov 08
Active, not recruiting
Phase 2
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Sep 14
Active, not recruiting
Phase 2
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Start of enrollment: 2018 Apr 17
Completed
Phase 2
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Aug 13
Active, not recruiting
Phase 2
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Start of enrollment: 2018 May 24
Active, not recruiting
Phase 2, Phase 3
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations Start of enrollment: 2018 Nov 06
Active, not recruiting
Phase 2
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Nov 14
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL.
Woods-Swafford, W., Woods-Swafford, W., Julie A Wolfson, Allison C Grimes, Michelle Nuno, Charlotte L Kerber, Subhash Ramakrishnan, Melissa Beauchemin, David Dickens, ...> ;JCO Oncology Practice. 2024 Apr 1
3 citations
Clinical Features and Risk Factors Associated With Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19.
Woods-Swafford, W., Martin, S., Davis, E., Dai, C., Boal, L., Araya, B., Brackett, J., Dickens, D., Kahn, A., Martinez, I., Sharma, A., Schwalm, C., Aguayo-Hiraldo, P....> ;JAMA Oncology. 2023 Aug 1
59 citations
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Jacqueline Halton, Leonardo R. Brandão, Matteo Luciani, Lisa Bomgaars, Elizabeth Chalmers, Lesley G. Mitchell, Ildar Nurmeev, Anjali Sharathkumar, Pavel Svirin, Kirill...> ;The Lancet. Haematology. 2021 Jan 1
Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.
Eckstein OS, Visser J, Rodriguez-Galindo C, Allen CE, NACHO-LIBRE Study Group> ;Blood. 2019-02-04
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and G...
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Lets...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015-06-01
Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
Wendy Woods-Swafford, Cindy L. Vnencak-Jones, Michael R. Loken, Becky Manes, Haydar Frangoul> ;Pediatric Blood & Cancer. 2008 Mar 1
Join now to see all

Press Mentions

Here’s Why a 3-Year-Old Iowa Girl May Not Get Cancer-Fighting DrugsApril 19th, 2023
Winter Respiratory Viruses Push Blank Children's Hospital to CapacityAugust 10th, 2021
Doctor: Children's Lives at Stake Due to Nationwide Drug ShortageOctober 18th, 2019
Join now to see all

Grant Support

Infrastructure Grant Psychosocial SupportSt. Baldricks2023–2024
Infrastructure Grant AYASt. Baldricks2022–2023
Infrastructure Grant for AYA and Survivorship CRASt. Baldricks2021–2022
Infrastructure Award - Community Outreach NavigatorSt. Baldricks2019–2020
Infrastructure Award - Social Services Coordination for Patients and FamiliesSt. Baldrick's2018–2019
Hyundai Impact GrantHyundai Hope on Wheels2018